No information is available on the clinical use of datopotamab deruxtecan during breastfeeding. Because datopotamab is a large protein molecule, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] However, datopotamab is conjugated with the small-molecule topoisomerase I inhibitor, deruxtecan, which might be excreted into milk and absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that breastfeeding be discontinued during therapy and for 1 month after the last dose.
关于datopotamab deruxtecan在母乳喂养期间的临床应用尚无可用信息。由于datopotamab是一种大分子蛋白质，乳汁中的含量可能非常低。[1]它也可能在婴儿胃肠道中部分被破坏，婴儿的吸收可能极少。[2]然而，datopotamab与小分子拓扑异构酶I抑制剂deruxtecan偶联，后者可能会排泄到乳汁中并被婴儿吸收。鉴于母乳喂养婴儿可能出现严重不良反应，制造商建议在治疗期间及最后一剂后1个月内停止母乳喂养。
Zotero 插件